---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-028369"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:25:10.977494+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics reports FY2024 net loss $317.4M; advances DYNE-101 and DYNE-251 toward accelerated approval

## Summary
- FDA granted Fast Track designation for DYNE-101 in DM1; registrational expansion cohort enrollment planned mid-2025.
- DYNE-251 in DMD: registrational expansion cohort enrollment targeted Q1 2025; data expected late 2025.
- Cash and equivalents $642.3M at Dec 31, 2024; plus $140.6M from ATM in Q1 2025; runway into H2 2026.
- Q4 2024 net loss $89.5M ($0.88 per share) vs $66.6M (Q4 2023); R&D expenses $81.8M (Q4 2024).
- Potential U.S. accelerated approval submissions for DYNE-101 in H1 2026 and DYNE-251 in early 2026.

## SEC filing metadata
- accession: 0000950170-25-028369
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017025028369/0000950170-25-028369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017025028369/dyn-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-028369
- JSON: https://secwatch.observer/filing/0000950170-25-028369.json
- Plain text: https://secwatch.observer/filing/0000950170-25-028369.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.